DURELLI, Luca
DURELLI, Luca
SCIENZE CLINICHE E BIOLOGICHE
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
2009-01-01 Paul O'Connor; Massimo Filippi; Barry Arnason; Giancarlo Comi; Stuart Cook; Douglas Goodin; Hans-Peter Hartung; Douglas Jeffery; Ludwig Kappos; Francis Boateng; Vitali Filippov; Maria Groth; Volker Knappertz; Christian Kraus; Rupert Sandbrink; Christoph Pohl; Timon Bogumil; for the BEYOND Study Group (including: Abramsky O; Achiron A; Agius M; Aichner F; Altenkirch H; Amato MP; Anten B; Arbizu T; Ash P; Ballario C; Bashir K; Baum K; Baumhackl U; Beaver G; Belova A; Berger J; Berger T; Berlit P; Beuche W; Bhan V; Bigley K; Bissay V; Blake C; Bö L; Boyko A; Brochet B; Brown M; Callegaro D; Carra A; Carroll W; Cascione M; Christie S; Clanet M; Clavelou P; Clementino VI; Confavreux C; Cooper J; Cree B; Cross A; Csanyi A; Czlonkowska A; D'Hooghe M; Damier P; Debouverie M; Defer G; Demina T; Deri N; Diem R; Dressel A; Dubois B; Dunne P; Duquette P; Durelli L; Edan G; Elias S; Elovaara I; Esfahani F; Evtushenko S; Fabijan TH; Fernández O; Ferreira ML; Fink A; Flechter S; Ford C; Francesconi C; Freedman M; Fryze W; Gabbai A; Gács G; Gallo P; Gazda S; Gerloff C; Glyman S; Goodman A; Gottesman M; Grand'Maison F; Guarnaccia J; Gutierrez A; Haas J; Hansen HJ; Hardiman O; Heard R; Heidenreich F; Herbert J; Herminia Scola R; Hodgkinson S; Hoffmann F; Holub R; Huddlestone J; Hughes B; Hughes M; Hunter S; Hurwitz B; Izquierdo G; Jacobasch E; Jacques F; Jakab G; Jongen P; Karageorgiou C; Karni A; Kasper L; Kaufman M; Keidel M; Khatri B; Kiefer R; Kirzinger S; Kita M; Komoly S; Kotov S; Kozubski W; Kumlien E; Kwiecinski H; Labouge P; LaGanke C; Lapierre Y; Lebrun-Frenay C; Leist T; Leon SA; Luetic G; Lynch S; Lynch T; Malkova N; Maltezou M; Markowitz C; Martin C; Mattle H; Mattson D; Metra M; Meyding-Lamadé U; Milo R; Milonas I; Miller A; Miller T; Minagar A; Mitchell G; Moreau T; Mosberg R; Murphy R; Nehrych T; Nikl J; Odinak M; Oschmann P; Owen King J; Pagani L; Pereira Damasceno B; Podemski R; Pöhlau D; Pozzilli C; Rammohan K; Reunanen M; Rice G; Richardson P; Rivera V; Rizvi S; Rogozhyn V; Rolak L; Rosenkranz T; Rotta R; Sanders E; Sater R; Satgur Gupta A; Schwartz R; Sedal L; Sega-Jazbec S; Selchen D; Selmaj K; Sheremata W; Shvets T; Silver D; Simsarian J; Skoromets A; Smiroldo J; Sokolova L; Solovyova Y; Sommer N; Spirin N; Stangel M; Stark E; Steinbrecher A; Stemper B; Stolyarov I; Strasser-Fuchs S; Sweeney B; Tettenborn B; Thrower B; Tilbery CP; Traboulsee A; Trojano M; Tubridy N; Tyor W; Valikovics A; Vermersch P; Vollmer T; Voloshyna N; Vrech C; Wajgt A; Weller B; Wendt J; Yakhno N; Yeung M; Zavalishin I.)
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b
2006-01-01 A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b
2006-01-01 A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A case of canomad (chronic ataxic neuropathy, ophthalmoplegia, igm paraprotein, cold agglutinins and disialosyl antibodies) with transient cognitive impairment.
2004-01-01 F. MELIS; M. REGGIANI; E. TREVISAN; P. BARBERO; M. IUDICELLO; R. SCIOLLA; L. DURELLI
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome
2009-01-01 Giulia Contessa; Stefania De Mercanti; Lorenza Delfico; Rossella Sciolla; mario Coletti Moja; Bruno Ferrero; Cinzia Ferrero; Paolo Ripellino; Emanuela Viglietta; Delon La Puma; Luca Durelli
A COCHRANE meta-analysis on the efficacy of recombinant interferon beta in preventing conversion of clinically isolated syndromes
2006-01-01 M. CLERICO; F. FAGGIANO; J. PALACE; M. TINTOR; G. RICE; L. DURELLI
A COCHRANE review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to Multiple Sclerosis
2006-01-01 M. CLERICO; M. TINTORE' SUBIRANA; J. PALACE; G. RICE; F. FAGGIANO; L. DURELLI
A comparison of fully automatic and semi-manual contouring software for quantitative magnetic resonance imaging of lesion load in multiple sclerosis
2005-01-01 E. Festa; P. Barbero; A. Pipieri; M. Bergui; A. Boghi; G. Bradac; L. Giordano; L. Durelli
A Meta-Analysis Of Methylprednisolone In Recovery From Multiple Sclerosis Exacerbations
2000-01-01 D.M. MILLER; B. WEINSTOCK-GUTTMAN; F. BTHOUX; J. LEE; G. BECK; V. BLOCK; L. DURELLI; L. LAMANTIA; D. BARNES; F. SELLEBJERG; R.A. RUDICK
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study.
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients.
2011-01-01 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
2006-01-01 Durelli, Luca; Barbero, Pierangelo; Clerico, Marinella
A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMISED EVALUATION); study: preliminary safety and tolerability data from a 2-year double-blind, randomised, multicentre, pilot study.
2004-01-01 E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; R. TOLA; D. CAPUTO; A.GHEZZI; E. SCARPINI; G. MEOLA; L. DURELLI
A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION) study: baseline data from a 2-years double blind, randomised, multicentre, pilot study.
2005-01-01 E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; M.R. TOLA; D. CAPUTO; A. GHEZZI; E. SCARPINI; G. MEOLA; P. CAVALLA; L. PROVINCIALI; M.G. MARROSU; L. DURELLI
A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION) study: baseline data from a 2-years double blind, randomized, multicentre, pilot study.
2005-01-01 E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; M.R. TOLA; D. CAPUTO; A. GHEZZI; E. SCARPINI; G. MEOLA; L. PROVINCIALI; P. CAVALLA; M.G. MARROSU; L. DURELLI; AND THE ITALIAN A.S.P.I.R.E. GROUP
A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION), study: preliminary safety and tolerability data from a 2-year double blind, randomized, multicentre, pilot study
2004-01-01 E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; M.R. TOLA; D. CAPUTO; A. GHEZZI; E. SCARPINI; G. MEOLA; L. DURELLI; THE ITALIAN A.S.P.I.R.E. GROUP
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
2017-01-01 Clerico, Marinella; De Mercanti, Stefania; Artusi, Carlo Alberto; Durelli, Luca; Naismith, Robert T
Adherence to interferon-beta treatment and results of therapy switching
2007-01-01 Clerico, Marinella; Barbero, Pierangelo; Contessa, Giulia; Ferrero, Cinzia; Durelli, Luca
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
2012-01-01 Alasdair J Coles,Cary L Twyman,Douglas L Arnold,Jeffrey A Cohen,Christian Confavreux,Edward J Fox,Hans-Peter Hartung,Eva Havrdova,Krzysztof W Selmaj,Howard L Weiner,Tamara Miller,Elizabeth Fisher,Rupert Sandbrink,Stephen L Lake,David H Margolin,Pedro Oyuela,Michael A Panzara,D Alastair S Compston, and the CARE-MS II investigators: Ajay S. Gupta, Edward Fox, Steven A. Glyman, Timothy K. Thoits, Herman C. Sullivan, Mark C. Cascione, Kottil W. Rammohan, Suzanne K. Gazda, Daniel R. Wynn, Sibyl E. Wray, Stanton Elias, Corey C. Ford, Andrew Goodman, Bruce L. Hughes; Omar Azhar Khan, Anand G. Vaishnav, Stephen Kirzinger, Sharon G. Lynch, David H. Mattson, Tiffany J. Braley, Daniel D. Mikol, Stephen Krieger, Tamara Ann Miller, Peter N. Riskind, Roberto Bomprezzi, Dean M. Wingerchuk, Brian Steingo, Jeffrey Alan Cohen, Heidi J. Crayton, Cary L. Twyman, Joanna A. Cooper, Leslie P. Weiner, Harold Moses Jr., Mark A. Agius, Ann Doan-Do Bass, Enrico C. Lallana, Galen W. Mitchell, Stanley J. Krolczyk, Alireza Minagar, Burk Jubelt, Bradley K. Evans, Samuel F. Hunter, Syed A. Rizvi, Christopher A. Sheppard, WM. David Honeycutt, Joseph Herbert, Ellen S. Lathi, Gabriel Pardo, Lily Jung Ilenson, Ted L. Rothstein, Ben W. Thrower, Mary Ann Picone, Mariko Kita, Erica M. Grazioli, Scott L. Silliman, Thomas Giancarlo, Malcolm H. Gottesman, Nuhad E. Abou Zeid, Vernon D. Rowe, Christine M. Boutwell, John D. Schaeffer, Claire S Riley, Keith R. Edwards, Jeanette K. Wendt, G. Kim Bigley Jr., Richard A. Shubin, Silva Markovic-Plese, Davis E. Jones, Gary Clauser, Mark S. Freedman, Francois Grand’Maison, Francois H. Jacques, Anthony L. Traboulsee, Donald G. Brunet, Marcelo Kremenchutzky, Charles Ayotte, Neil S. Lava, Stephen R. Waldman, Todd J. Janus, Stephen Gerard Vincent, Mark Gudesblatt, Michael Rossen, Lee S. Stein, Bennett-Irving Machanic, Timothy Vollmer, Jeffrey S. Gitt, Jeffrey Dunn, Donald Negroski, Mark H. Fletcher, Adil Javed, Elliot M. Frohman, Richard Macdonell, John Owen King, Mark A. Paine, Karyn Boundy, Simon Broadley, Steve Vucic, Stephen Reddel, Michael D. Dreyer, Raymond Schwartz, Pamela Ann McCombe, Suzanne Hodgkinson, Charles Tilbery, Maria Lucia B. Ferreira, Dagoberto Callegaro, Marcio Mena Barreto Martins, Jesus Arturo Violante Villanueva, Noemi Santos Caballero, Claudia Venzor Mendoza, Norma Haydee Deri, Alasdair Coles, Neil James Scolding, Gavin Giovannoni, Basil Sharrack, David J. Rog, Giancarlo Comi, Angelo Ghezzi, MD, Giovanni L. Mancardi, Luca Durelli, Antonio Bertolotto, Ruggero Capra, Carlo Pozzilli, Maria Giovanna Marrosu, Raymond M. M. Hupperts, Erik van Munster, Xavier Montalbán, Rafael Arroyo González, Guillermo Izquierdo Ayuso, Óscar Fernández Fernández, Christian Confavreux, Patrick Vermersch, Jerome de Seze, Thibault Moreau, Pierre Clavelou, Catherine Lubetzki, Michel Clanet, Marc Debouverie, Gilles Edan, Hans-Peter Hartung, Judith Haas, Martin Stangel, Tjalf Ziemssen, Bernhard Hemmer, Karl Baum, U. Klaus Zettl, U. Herrlinger, Wolfgang Köhler, Gunter Ochs, Patrick Oschmann, Klaus Tiel-Wilck, Hayrettin Tumani, Peter P. Urban, Jan Lycke, Anders Svenningsson, Ivana Kovarova, Marta Vachova, Ivan Rektor, Radomir Talab, Krzysztof Selmaj, Zbigniew Stelmasiak, Wojciech Kozubski, Benedicte D. P. Dubois, Dominique Dive, Christian Sindic, Karl Vass, Per Soelberg Sørensen, Thor Petersen, Mads Ravnborg, Anat Achiron, Adi Vaknin Dembinsky, Arnon Karni, Evgeny I. Gusev, Igor D. Stolyarov, Igor A. Zavalishin, Alexander A. Skoromets, Alexei N. Boyko, Anna N. Belova, Nadezhda A. Malkova, Evgeniy R. Barantsevich, Eduard Z. Yakupov, Semen V. Perfiliev, Irina E. Poverennova, Natalia P. Voloshyna, Tetyana I. Nehrych, Tetyana O. Kobys, Mario Habek, Vesna Brinar, Zlatko Trkanjec, Anton Vladić, Spomenka Kidemet Piskać, Licia Antonelli, Jelena Drulović, Čongor Nadj, Evica Dinčić, Gordana Tončev
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months
2016-01-01 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study | 2009 | Paul O'Connor; Massimo Filippi; Barry Arnason; Giancarlo Comi; Stuart Cook; Douglas Goodin; Hans-Peter Hartung; Douglas Jeffery; Ludwig Kappos; Francis Boateng; Vitali Filippov; Maria Groth; Volker Knappertz; Christian Kraus; Rupert Sandbrink; Christoph Pohl; Timon Bogumil; for the BEYOND Study Group (including: Abramsky O; Achiron A; Agius M; Aichner F; Altenkirch H; Amato MP; Anten B; Arbizu T; Ash P; Ballario C; Bashir K; Baum K; Baumhackl U; Beaver G; Belova A; Berger J; Berger T; Berlit P; Beuche W; Bhan V; Bigley K; Bissay V; Blake C; Bö L; Boyko A; Brochet B; Brown M; Callegaro D; Carra A; Carroll W; Cascione M; Christie S; Clanet M; Clavelou P; Clementino VI; Confavreux C; Cooper J; Cree B; Cross A; Csanyi A; Czlonkowska A; D'Hooghe M; Damier P; Debouverie M; Defer G; Demina T; Deri N; Diem R; Dressel A; Dubois B; Dunne P; Duquette P; Durelli L; Edan G; Elias S; Elovaara I; Esfahani F; Evtushenko S; Fabijan TH; Fernández O; Ferreira ML; Fink A; Flechter S; Ford C; Francesconi C; Freedman M; Fryze W; Gabbai A; Gács G; Gallo P; Gazda S; Gerloff C; Glyman S; Goodman A; Gottesman M; Grand'Maison F; Guarnaccia J; Gutierrez A; Haas J; Hansen HJ; Hardiman O; Heard R; Heidenreich F; Herbert J; Herminia Scola R; Hodgkinson S; Hoffmann F; Holub R; Huddlestone J; Hughes B; Hughes M; Hunter S; Hurwitz B; Izquierdo G; Jacobasch E; Jacques F; Jakab G; Jongen P; Karageorgiou C; Karni A; Kasper L; Kaufman M; Keidel M; Khatri B; Kiefer R; Kirzinger S; Kita M; Komoly S; Kotov S; Kozubski W; Kumlien E; Kwiecinski H; Labouge P; LaGanke C; Lapierre Y; Lebrun-Frenay C; Leist T; Leon SA; Luetic G; Lynch S; Lynch T; Malkova N; Maltezou M; Markowitz C; Martin C; Mattle H; Mattson D; Metra M; Meyding-Lamadé U; Milo R; Milonas I; Miller A; Miller T; Minagar A; Mitchell G; Moreau T; Mosberg R; Murphy R; Nehrych T; Nikl J; Odinak M; Oschmann P; Owen King J; Pagani L; Pereira Damasceno B; Podemski R; Pöhlau D; Pozzilli C; Rammohan K; Reunanen M; Rice G; Richardson P; Rivera V; Rizvi S; Rogozhyn V; Rolak L; Rosenkranz T; Rotta R; Sanders E; Sater R; Satgur Gupta A; Schwartz R; Sedal L; Sega-Jazbec S; Selchen D; Selmaj K; Sheremata W; Shvets T; Silver D; Simsarian J; Skoromets A; Smiroldo J; Sokolova L; Solovyova Y; Sommer N; Spirin N; Stangel M; Stark E; Steinbrecher A; Stemper B; Stolyarov I; Strasser-Fuchs S; Sweeney B; Tettenborn B; Thrower B; Tilbery CP; Traboulsee A; Trojano M; Tubridy N; Tyor W; Valikovics A; Vermersch P; Vollmer T; Voloshyna N; Vrech C; Wajgt A; Weller B; Wendt J; Yakhno N; Yeung M; Zavalishin I.) | |
| A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b | 2006 | A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b | 2006 | A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| A case of canomad (chronic ataxic neuropathy, ophthalmoplegia, igm paraprotein, cold agglutinins and disialosyl antibodies) with transient cognitive impairment. | 2004 | F. MELIS; M. REGGIANI; E. TREVISAN; P. BARBERO; M. IUDICELLO; R. SCIOLLA; L. DURELLI | |
| A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome | 2009 | Giulia Contessa; Stefania De Mercanti; Lorenza Delfico; Rossella Sciolla; mario Coletti Moja; Bruno Ferrero; Cinzia Ferrero; Paolo Ripellino; Emanuela Viglietta; Delon La Puma; Luca Durelli | |
| A COCHRANE meta-analysis on the efficacy of recombinant interferon beta in preventing conversion of clinically isolated syndromes | 2006 | M. CLERICO; F. FAGGIANO; J. PALACE; M. TINTOR; G. RICE; L. DURELLI | |
| A COCHRANE review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to Multiple Sclerosis | 2006 | M. CLERICO; M. TINTORE' SUBIRANA; J. PALACE; G. RICE; F. FAGGIANO; L. DURELLI | |
| A comparison of fully automatic and semi-manual contouring software for quantitative magnetic resonance imaging of lesion load in multiple sclerosis | 2005 | E. Festa; P. Barbero; A. Pipieri; M. Bergui; A. Boghi; G. Bradac; L. Giordano; L. Durelli | |
| A Meta-Analysis Of Methylprednisolone In Recovery From Multiple Sclerosis Exacerbations | 2000 | D.M. MILLER; B. WEINSTOCK-GUTTMAN; F. BTHOUX; J. LEE; G. BECK; V. BLOCK; L. DURELLI; L. LAMANTIA; D. BARNES; F. SELLEBJERG; R.A. RUDICK | |
| A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. | 2004 | E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI | |
| A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. | 2011 | Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli | |
| A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis | 2006 | Durelli, Luca; Barbero, Pierangelo; Clerico, Marinella | |
| A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMISED EVALUATION); study: preliminary safety and tolerability data from a 2-year double-blind, randomised, multicentre, pilot study. | 2004 | E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; R. TOLA; D. CAPUTO; A.GHEZZI; E. SCARPINI; G. MEOLA; L. DURELLI | |
| A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION) study: baseline data from a 2-years double blind, randomised, multicentre, pilot study. | 2005 | E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; M.R. TOLA; D. CAPUTO; A. GHEZZI; E. SCARPINI; G. MEOLA; P. CAVALLA; L. PROVINCIALI; M.G. MARROSU; L. DURELLI | |
| A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION) study: baseline data from a 2-years double blind, randomized, multicentre, pilot study. | 2005 | E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; M.R. TOLA; D. CAPUTO; A. GHEZZI; E. SCARPINI; G. MEOLA; L. PROVINCIALI; P. CAVALLA; M.G. MARROSU; L. DURELLI; AND THE ITALIAN A.S.P.I.R.E. GROUP | |
| A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION), study: preliminary safety and tolerability data from a 2-year double blind, randomized, multicentre, pilot study | 2004 | E. MONTANARI; L. MANNESCHI; I. PESCI; E. MERELLI; L. MOTTI; M.R. TOLA; D. CAPUTO; A. GHEZZI; E. SCARPINI; G. MEOLA; L. DURELLI; THE ITALIAN A.S.P.I.R.E. GROUP | |
| Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab | 2017 | Clerico, Marinella; De Mercanti, Stefania; Artusi, Carlo Alberto; Durelli, Luca; Naismith, Robert T | |
| Adherence to interferon-beta treatment and results of therapy switching | 2007 | Clerico, Marinella; Barbero, Pierangelo; Contessa, Giulia; Ferrero, Cinzia; Durelli, Luca | |
| Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial | 2012 | Alasdair J Coles,Cary L Twyman,Douglas L Arnold,Jeffrey A Cohen,Christian Confavreux,Edward J Fox,Hans-Peter Hartung,Eva Havrdova,Krzysztof W Selmaj,Howard L Weiner,Tamara Miller,Elizabeth Fisher,Rupert Sandbrink,Stephen L Lake,David H Margolin,Pedro Oyuela,Michael A Panzara,D Alastair S Compston, and the CARE-MS II investigators: Ajay S. Gupta, Edward Fox, Steven A. Glyman, Timothy K. Thoits, Herman C. Sullivan, Mark C. Cascione, Kottil W. Rammohan, Suzanne K. Gazda, Daniel R. Wynn, Sibyl E. Wray, Stanton Elias, Corey C. Ford, Andrew Goodman, Bruce L. Hughes; Omar Azhar Khan, Anand G. Vaishnav, Stephen Kirzinger, Sharon G. Lynch, David H. Mattson, Tiffany J. Braley, Daniel D. Mikol, Stephen Krieger, Tamara Ann Miller, Peter N. Riskind, Roberto Bomprezzi, Dean M. Wingerchuk, Brian Steingo, Jeffrey Alan Cohen, Heidi J. Crayton, Cary L. Twyman, Joanna A. Cooper, Leslie P. Weiner, Harold Moses Jr., Mark A. Agius, Ann Doan-Do Bass, Enrico C. Lallana, Galen W. Mitchell, Stanley J. Krolczyk, Alireza Minagar, Burk Jubelt, Bradley K. Evans, Samuel F. Hunter, Syed A. Rizvi, Christopher A. Sheppard, WM. David Honeycutt, Joseph Herbert, Ellen S. Lathi, Gabriel Pardo, Lily Jung Ilenson, Ted L. Rothstein, Ben W. Thrower, Mary Ann Picone, Mariko Kita, Erica M. Grazioli, Scott L. Silliman, Thomas Giancarlo, Malcolm H. Gottesman, Nuhad E. Abou Zeid, Vernon D. Rowe, Christine M. Boutwell, John D. Schaeffer, Claire S Riley, Keith R. Edwards, Jeanette K. Wendt, G. Kim Bigley Jr., Richard A. Shubin, Silva Markovic-Plese, Davis E. Jones, Gary Clauser, Mark S. Freedman, Francois Grand’Maison, Francois H. Jacques, Anthony L. Traboulsee, Donald G. Brunet, Marcelo Kremenchutzky, Charles Ayotte, Neil S. Lava, Stephen R. Waldman, Todd J. Janus, Stephen Gerard Vincent, Mark Gudesblatt, Michael Rossen, Lee S. Stein, Bennett-Irving Machanic, Timothy Vollmer, Jeffrey S. Gitt, Jeffrey Dunn, Donald Negroski, Mark H. Fletcher, Adil Javed, Elliot M. Frohman, Richard Macdonell, John Owen King, Mark A. Paine, Karyn Boundy, Simon Broadley, Steve Vucic, Stephen Reddel, Michael D. Dreyer, Raymond Schwartz, Pamela Ann McCombe, Suzanne Hodgkinson, Charles Tilbery, Maria Lucia B. Ferreira, Dagoberto Callegaro, Marcio Mena Barreto Martins, Jesus Arturo Violante Villanueva, Noemi Santos Caballero, Claudia Venzor Mendoza, Norma Haydee Deri, Alasdair Coles, Neil James Scolding, Gavin Giovannoni, Basil Sharrack, David J. Rog, Giancarlo Comi, Angelo Ghezzi, MD, Giovanni L. Mancardi, Luca Durelli, Antonio Bertolotto, Ruggero Capra, Carlo Pozzilli, Maria Giovanna Marrosu, Raymond M. M. Hupperts, Erik van Munster, Xavier Montalbán, Rafael Arroyo González, Guillermo Izquierdo Ayuso, Óscar Fernández Fernández, Christian Confavreux, Patrick Vermersch, Jerome de Seze, Thibault Moreau, Pierre Clavelou, Catherine Lubetzki, Michel Clanet, Marc Debouverie, Gilles Edan, Hans-Peter Hartung, Judith Haas, Martin Stangel, Tjalf Ziemssen, Bernhard Hemmer, Karl Baum, U. Klaus Zettl, U. Herrlinger, Wolfgang Köhler, Gunter Ochs, Patrick Oschmann, Klaus Tiel-Wilck, Hayrettin Tumani, Peter P. Urban, Jan Lycke, Anders Svenningsson, Ivana Kovarova, Marta Vachova, Ivan Rektor, Radomir Talab, Krzysztof Selmaj, Zbigniew Stelmasiak, Wojciech Kozubski, Benedicte D. P. Dubois, Dominique Dive, Christian Sindic, Karl Vass, Per Soelberg Sørensen, Thor Petersen, Mads Ravnborg, Anat Achiron, Adi Vaknin Dembinsky, Arnon Karni, Evgeny I. Gusev, Igor D. Stolyarov, Igor A. Zavalishin, Alexander A. Skoromets, Alexei N. Boyko, Anna N. Belova, Nadezhda A. Malkova, Evgeniy R. Barantsevich, Eduard Z. Yakupov, Semen V. Perfiliev, Irina E. Poverennova, Natalia P. Voloshyna, Tetyana I. Nehrych, Tetyana O. Kobys, Mario Habek, Vesna Brinar, Zlatko Trkanjec, Anton Vladić, Spomenka Kidemet Piskać, Licia Antonelli, Jelena Drulović, Čongor Nadj, Evica Dinčić, Gordana Tončev | |
| Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months | 2016 | Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M |